[go: up one dir, main page]

WO2010012045A8 - Vaccins contre la grippe - Google Patents

Vaccins contre la grippe Download PDF

Info

Publication number
WO2010012045A8
WO2010012045A8 PCT/AU2009/000983 AU2009000983W WO2010012045A8 WO 2010012045 A8 WO2010012045 A8 WO 2010012045A8 AU 2009000983 W AU2009000983 W AU 2009000983W WO 2010012045 A8 WO2010012045 A8 WO 2010012045A8
Authority
WO
WIPO (PCT)
Prior art keywords
influenza vaccines
subject
influenza virus
gamma
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AU2009/000983
Other languages
English (en)
Other versions
WO2010012045A1 (fr
Inventor
Mohammed Alsharifi
Arno Mullbacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gamma Vaccines Pty Ltd
Original Assignee
Gamma Vaccines Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP09802286.6A priority Critical patent/EP2318044B1/fr
Priority to JP2011520282A priority patent/JP5689796B2/ja
Priority to CN200980138757.4A priority patent/CN102170902B/zh
Priority to US13/056,932 priority patent/US20110150926A1/en
Priority to AU2009276304A priority patent/AU2009276304B2/en
Priority to CA2733356A priority patent/CA2733356C/fr
Priority to KR1020117005024A priority patent/KR101707569B1/ko
Application filed by Gamma Vaccines Pty Ltd filed Critical Gamma Vaccines Pty Ltd
Publication of WO2010012045A1 publication Critical patent/WO2010012045A1/fr
Anticipated expiration legal-status Critical
Priority to ZA2011/00962A priority patent/ZA201100962B/en
Publication of WO2010012045A8 publication Critical patent/WO2010012045A8/fr
Priority to US14/744,924 priority patent/US10251947B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C12N2760/16163—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention porte sur un procédé pour le traitement ou la prévention d'une infection par le virus de la grippe chez un sujet. Ce procédé comprend l'administration au sujet d'une quantité thérapeutiquement efficace d'un virus de la grippe irradié par des rayons gamma.
PCT/AU2009/000983 2008-08-01 2009-07-31 Vaccins contre la grippe Ceased WO2010012045A1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2011520282A JP5689796B2 (ja) 2008-08-01 2009-07-31 インフルエンザワクチン
CN200980138757.4A CN102170902B (zh) 2008-08-01 2009-07-31 流感疫苗
US13/056,932 US20110150926A1 (en) 2008-08-01 2009-07-31 Influenza vaccines
AU2009276304A AU2009276304B2 (en) 2008-08-01 2009-07-31 Influenza vaccines
CA2733356A CA2733356C (fr) 2008-08-01 2009-07-31 Vaccins contre la grippe
EP09802286.6A EP2318044B1 (fr) 2008-08-01 2009-07-31 Vaccins contre la grippe
KR1020117005024A KR101707569B1 (ko) 2008-08-01 2009-07-31 인플루엔자 백신
ZA2011/00962A ZA201100962B (en) 2008-08-01 2011-02-07 Influenza vaccines
US14/744,924 US10251947B2 (en) 2008-08-01 2015-06-19 Influenza vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8580208P 2008-08-01 2008-08-01
US61/085,802 2008-08-01

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/056,932 A-371-Of-International US20110150926A1 (en) 2008-08-01 2009-07-31 Influenza vaccines
US14/744,924 Continuation US10251947B2 (en) 2008-08-01 2015-06-19 Influenza vaccines

Publications (2)

Publication Number Publication Date
WO2010012045A1 WO2010012045A1 (fr) 2010-02-04
WO2010012045A8 true WO2010012045A8 (fr) 2011-02-10

Family

ID=41609853

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2009/000983 Ceased WO2010012045A1 (fr) 2008-08-01 2009-07-31 Vaccins contre la grippe

Country Status (11)

Country Link
US (2) US20110150926A1 (fr)
EP (1) EP2318044B1 (fr)
JP (1) JP5689796B2 (fr)
KR (1) KR101707569B1 (fr)
CN (1) CN102170902B (fr)
AU (1) AU2009276304B2 (fr)
CA (1) CA2733356C (fr)
MY (1) MY172788A (fr)
RU (1) RU2011107757A (fr)
WO (1) WO2010012045A1 (fr)
ZA (1) ZA201100962B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines
US9687536B2 (en) 2010-04-15 2017-06-27 Shin Nippon Biomedical Laboratories, Ltd. Methods and compositions for intranasal delivery
WO2011133997A1 (fr) * 2010-04-28 2011-11-03 Gamma Vaccines Pty Limited Vaccins antigrippaux à réaction croisée
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
US20140079732A1 (en) * 2011-01-27 2014-03-20 Gamma Vaccines Pty Limited Combination vaccines
CN105362217B (zh) * 2015-11-25 2018-07-06 孙维星 一种结膜囊冲洗液及其制备方法
CN113395980B (zh) 2019-01-08 2023-09-15 韩国原子力研究院 利用放射线制备减毒活疫苗的方法及通过其制备的减毒活疫苗组合物
WO2021231923A1 (fr) * 2020-05-14 2021-11-18 Metaclipse Therapeutics Corporation Compositions et méthodes de détection et de traitement d'une infection à sras-cov-2

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3259546A (en) * 1962-06-01 1966-07-05 Canadian Patents Dev Treatment of viruses
US3567938A (en) * 1968-02-14 1971-03-02 Credo Inc Gamma ray laser
US3557370A (en) * 1968-02-14 1971-01-19 Dawson Inc Alexander Gamma ray laser having a low temperature closed resonating cavity
ES2062530T3 (es) * 1989-05-01 1994-12-16 Alkermes Inc Procedimiento para producir particulas pequeñas de moleculas biologicamente activas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
EP0761231B1 (fr) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Composition vaccinale contenant des adjuvants
EP0620277A1 (fr) 1993-03-18 1994-10-19 Merck & Co. Inc. Acides nucléiques comme produits pharmaceutiques
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (fr) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Oligonucleotides immunomodulateurs
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US6146873A (en) * 1994-11-10 2000-11-14 Baxter Aktiengesellschaft Production of orthomyxoviruses in monkey kidney cells using protein-free media
US5698433A (en) * 1994-11-10 1997-12-16 Immuno Ag Method for producing influenza virus and vaccine
US5753489A (en) * 1994-11-10 1998-05-19 Immuno Ag Method for producing viruses and vaccines in serum-free culture
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5840565A (en) * 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
DE60142506D1 (de) * 2000-03-03 2010-08-19 Chemo Sero Therapeut Res Inst In serumfreier kultur verwendbare zelle, kultursuspension und verfahren zur virusproduktion als impfstoff unter verwendung der zelle
US20040096463A1 (en) 2001-02-23 2004-05-20 Nathalie Garcon Novel vaccine
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
DE602004028736D1 (de) * 2003-06-20 2010-09-30 Microbix Biosystems Inc Verbesserungen bei der virusproduktion
US7037707B2 (en) 2003-09-04 2006-05-02 St. Jude Children's Research Hospital Method for generating influenza viruses and vaccines
WO2005113756A1 (fr) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Methode
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
AR059972A1 (es) * 2006-03-22 2008-05-14 Solvay Pharm Bv Administracion intranasal o inhalacional de virosomas
GB0614460D0 (en) * 2006-07-20 2006-08-30 Novartis Ag Vaccines
WO2008073490A1 (fr) * 2006-12-12 2008-06-19 Carrington Laboratories Inc., Purification d'antigènes viraux de la grippe
MY172788A (en) 2008-08-01 2019-12-12 Gamma Vaccines Pty Ltd Influenza vaccines

Also Published As

Publication number Publication date
MY172788A (en) 2019-12-12
AU2009276304A1 (en) 2010-02-04
US10251947B2 (en) 2019-04-09
CN102170902B (zh) 2015-07-15
KR101707569B1 (ko) 2017-02-16
WO2010012045A1 (fr) 2010-02-04
US20110150926A1 (en) 2011-06-23
EP2318044A1 (fr) 2011-05-11
CA2733356C (fr) 2016-06-07
JP5689796B2 (ja) 2015-03-25
CN102170902A (zh) 2011-08-31
US20150283224A1 (en) 2015-10-08
CA2733356A1 (fr) 2010-02-04
KR20110053345A (ko) 2011-05-20
ZA201100962B (en) 2012-05-30
JP2011529856A (ja) 2011-12-15
AU2009276304B2 (en) 2012-10-11
EP2318044A4 (fr) 2012-11-14
EP2318044B1 (fr) 2015-12-02
RU2011107757A (ru) 2012-09-10

Similar Documents

Publication Publication Date Title
WO2010012045A8 (fr) Vaccins contre la grippe
IL269370B (en) Chemicals, preparations and methods for the treatment and prevention of orthopoxvirus infections and related diseases
AP2010005480A0 (en) Small molecule inhibitors for the treatment or prevention of denque virus infection.
SG179082A1 (en) Method for the preparation of an influenza virus
IL186611A0 (en) Vaccine against pandemic strains of influenza viruses
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
MX2012000035A (es) Antigenos de virus de sincicio respiratorio recombinantes.
BRPI1014322A2 (pt) Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
WO2009089494A3 (fr) Compositions pharmaceutiques
WO2008115281A3 (fr) Composés de traitement d'infections virales
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
EP4219566A3 (fr) Antigènes du vrs recombinants
ZA201101814B (en) Prevention, treatment and diagnosis of p.gingivalis infection
WO2010111640A3 (fr) Compositions antigrippales et méthodes associées
WO2013006569A3 (fr) Vaccin contre le virus de l'herpès et procédés d'utilisation
IL202450A (en) Pharmaceutical composition to treat influenza virus infection
PH12015501637A1 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
DK3006038T3 (da) Enkeltdoser af oritavancin til behandling eller forebyggelse af en bakterieinfektion
EP2601967A4 (fr) Médicament destiné à la prévention et au traitement des maladies provoquées par le vih ou associées au vih, y compris du sida
WO2010034974A3 (fr) Vaccin tb
EP2538970A4 (fr) Traitement ou prévention d'une infection
AU2006309007A8 (en) Use of vaccines for the treatment/ prevention of the transmission of influenza pathogens between species
WO2010138419A3 (fr) Matières et procédés de traitement d'infections virales
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.
WO2010128016A3 (fr) Agonistes du récepteur par2 utilisés dans le traitement ou la prévention des infections du virus de la grippe a

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980138757.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09802286

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009276304

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2011520282

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2733356

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 965/CHENP/2011

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009276304

Country of ref document: AU

Date of ref document: 20090731

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009802286

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011107757

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 20117005024

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13056932

Country of ref document: US